Brief: Fusen Pharmaceutical Says Dydrogesterone Tablet Receives Marketing Approval From PRC NMPA
27/04/2026 16:25
April 27 (Reuters) - Fusen Pharmaceutical Co Ltd 1652.HK: DYDROGESTERONE TABLET RECEIVES MARKETING APPROVAL FROM PRC NATIONAL MEDICAL PRODUCTS ADMINISTRATION Further company coverage: 1652.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA